Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
XB-002 by Exelixis for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
XB-002 by Exelixis for Fallopian Tube Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
XB-002 by Exelixis for Breast Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Breast Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to...
XB-002 by Exelixis for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
XB-002 by Exelixis for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
XB-002 by Exelixis for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
XB-002 by Exelixis for Peritoneal Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Cervical Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Colorectal Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Pancreatic Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Epithelial Ovarian Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
XB-002 by Exelixis for Oral Cavity (Mouth) Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
XB-002 by Exelixis for Oropharyngeal Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Laryngeal Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Hypopharyngeal Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Non-Small Cell Lung Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
XB-002 by Exelixis for Endometrial Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Exelixis's XB-002?
XB-002 is a monoclonal antibody conjugated commercialized by Exelixis, with a leading Phase II program in Esophageal Squamous Cell Carcinoma...